Roivant Sciences Net Worth
Roivant Sciences Net Worth Breakdown | ROIV |
Roivant Sciences Net Worth Analysis
Roivant Sciences' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Roivant Sciences' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Roivant Sciences' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Roivant Sciences' net worth analysis. One common approach is to calculate Roivant Sciences' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Roivant Sciences' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Roivant Sciences' net worth. This approach calculates the present value of Roivant Sciences' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Roivant Sciences' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Roivant Sciences' net worth. This involves comparing Roivant Sciences' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Roivant Sciences' net worth relative to its peers.
Enterprise Value |
|
To determine if Roivant Sciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Roivant Sciences' net worth research are outlined below:
| Roivant Sciences generated a negative expected return over the last 90 days | |
| Roivant Sciences currently holds about 1.94 B in cash with (765.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.76. | |
| Over 80.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Roivant to Host Investor Webcast at 800 AM ET on Wednesday, March 19 to Review Results from ... |
Roivant Sciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Roivant Sciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Roivant Sciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 12th of February 2024 Upcoming Quarterly Report | View | |
| 26th of June 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of June 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of March 2023 Last Financial Announcement | View |
Know Roivant Sciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Roivant Sciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Roivant Sciences backward and forwards among themselves. Roivant Sciences' institutional investor refers to the entity that pools money to purchase Roivant Sciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Amvescap Plc. | 2024-12-31 | 9.5 M | Geode Capital Management, Llc | 2024-12-31 | 7.8 M | Woodline Partners Lp | 2024-12-31 | 6.1 M | Toms Capital Investment Management Lp | 2024-12-31 | 5.9 M | Adage Capital Partners Gp Llc | 2024-12-31 | 5.7 M | Ubs Group Ag | 2024-12-31 | 5.3 M | Anchorage Advisors, Llc | 2024-12-31 | 4.8 M | Norges Bank | 2024-12-31 | 4.4 M | Blackbarn Capital Partners Lp | 2024-12-31 | 4.1 M | Qvt Financial Lp | 2024-12-31 | 65.8 M | Sb Investment Advisers (uk) Ltd | 2024-12-31 | 62.1 M |
Follow Roivant Sciences' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 7.74 B.Market Cap |
|
Project Roivant Sciences' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.55 | 0.58 | |
| Return On Capital Employed | 0.55 | 0.58 | |
| Return On Assets | 0.54 | 0.57 | |
| Return On Equity | 0.84 | 0.88 |
When accessing Roivant Sciences' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Roivant Sciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Roivant Sciences' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Roivant Sciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Roivant Sciences. Check Roivant Sciences' Beneish M Score to see the likelihood of Roivant Sciences' management manipulating its earnings.
Evaluate Roivant Sciences' management efficiency
Roivant Sciences has return on total asset (ROA) of (0.1162) % which means that it has lost $0.1162 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1464) %, meaning that it created substantial loss on money invested by shareholders. Roivant Sciences' management efficiency ratios could be used to measure how well Roivant Sciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to 0.58 in 2025. Return On Capital Employed is likely to climb to 0.58 in 2025. At this time, Roivant Sciences' Return On Assets are fairly stable compared to the past year. Asset Turnover is likely to climb to 0.02 in 2025, whereas Non Currrent Assets Other are likely to drop slightly above 32.7 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 9.47 | 5.83 | |
| Tangible Book Value Per Share | 9.27 | 5.75 | |
| Enterprise Value Over EBITDA | 0.45 | 0.47 | |
| Price Book Value Ratio | 1.23 | 2.04 | |
| Enterprise Value Multiple | 0.45 | 0.47 | |
| Price Fair Value | 1.23 | 2.04 | |
| Enterprise Value | 1.9 B | 2.1 B |
The operational strategies employed by Roivant Sciences management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Enterprise Value Revenue 21.1765 | Revenue | Quarterly Revenue Growth (0.42) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Roivant Sciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Roivant Sciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Roivant Sciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Roivant Sciences Corporate Filings
8K | 19th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 4th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 25th of February 2025 Other Reports | ViewVerify | |
| 14th of February 2025 Other Reports | ViewVerify |
Roivant Sciences Earnings per Share Projection vs Actual
Roivant Sciences Corporate Management
| Amy Mahery | Chief Officer | Profile | |
| Matthew Gline | CEO Director | Profile | |
| Marianne Romeo | Head Management | Profile | |
| Huafeng Xu | Chief Officer | Profile | |
| Josh Chen | General Counsel | Profile | |
| Matt Maisak | Chief Platforms | Profile | |
| Vivek Ramaswamy | Founder Chairman | Profile |
Additional Tools for Roivant Stock Analysis
When running Roivant Sciences' price analysis, check to measure Roivant Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roivant Sciences is operating at the current time. Most of Roivant Sciences' value examination focuses on studying past and present price action to predict the probability of Roivant Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roivant Sciences' price. Additionally, you may evaluate how the addition of Roivant Sciences to your portfolios can decrease your overall portfolio volatility.